Offer - Urjas Oil for just ₹ 1
Bigovas 500 Tablet SR is a prescription medicine that is available as a Tablet. Primarily, it is used for the treatment of Diabetes.
The right dosage of Bigovas 500 Tablet SR depends on the age, gender, and medical history of the patient. Individual symptoms and route of administration also determines the right dosage. This information has been provided in detail in the dosage section.
The most common side effects of Bigovas 500 Tablet SR are Stomach Upset, Difficulty urinating. Some other side effects of Bigovas 500 Tablet SR have been listed ahead. Usually, these side effects of Bigovas 500 Tablet SR go away soon, and do not persist beyond the duration of the treatment. Consult your doctor if these side effects become worse or stay for a longer duration.
In addition, Bigovas 500 Tablet SR's effect is Mild during pregnancy and Moderate for lactating mothers. Warnings related to Bigovas 500 Tablet SR's effects on the liver, heart and kidney, if any, have been listed below.
Individuals suffering from medical conditions like Congestive Heart Failure (CHF), Anemia, Shock must refrain from the use of Bigovas 500 Tablet SR since this can cause severe adverse effects. The section on Bigovas 500 Tablet SR contraindications lists all such conditions.
Additionally, Bigovas 500 Tablet SR may also adversely react with other medicines. See below for a complete list.
You should also be aware that Bigovas 500 Tablet SR is safe while driving, and is addiction.
Bigovas 500 Tablet SR is used to treat the following -
Main Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
13 - 18 years (Adolescent) |
|
2 - 12 years (Child) |
|
Based on research, the following side effects have been observed when Bigovas 500 Tablet SR is used -
Severe
Moderate
Mild
Common
Is the use of Bigovas 500 Tablet SR safe for pregnant women?
Bigovas has little to no side effects in pregnant women.
Is the use of Bigovas 500 Tablet SR safe during breastfeeding?
Women who are breastfeeding can experience some moderate side effects of Bigovas. Immediately discontinue Bigovas if you observe any side effects. Contact your doctor, and restart using it only if your doctor considers it safe for you.
What is the effect of Bigovas 500 Tablet SR on the Kidneys?
There are no side effects of Bigovas on the kidneys.
What is the effect of Bigovas 500 Tablet SR on the Liver?
Using Bigovas does not have any harmful effects on the liver.
What is the effect of Bigovas 500 Tablet SR on the Heart?
Bigovas is not harmful for the heart.
Bigovas 500 Tablet SR should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Bigovas 500 Tablet SR unless your doctor advises you to do so -
Is this Bigovas 500 Tablet SR habit forming or addictive?
Bigovas 500 Tablet SR is not addictive in nature.
Is it safe to drive or operate heavy machinery when consuming?
Yes, you can operate a vehicle or heavy machinery after taking Bigovas 500 Tablet SR since it does not cause drowsiness.
Is it safe?
Yes, but take Bigovas 500 Tablet SR only as per medical advice.
Is it able to treat mental disorders?
No, Bigovas 500 Tablet SR cannot treat any kind of mental disorder.
Interaction between Food and Bigovas 500 Tablet SR
There isn't any research available on the side effects of taking Bigovas 500 Tablet SR with food.
Interaction between Alcohol and Bigovas 500 Tablet SR
Taking Bigovas 500 Tablet SR with alcohol can have severely harmful effects on your health.
Bigovas is used with a proper diet and exercise program, to treat diabetes. It is also used with other medication to reduce the high blood sugar. It is used in a patient with type2 diabetes. It is also used in the treatment of polycystic ovarian syndrome (PCOS) and cancer.
Lactic acidosis associated with Bigovas treatment is a rare but fatal adverse effect. Lactic acidosis appears to result from biguanide interference causing an increase in production and decrease in clearance of lactate leading to higher cellular lactate levels. A decrease in pyruvate carboxylase activity, the rate-limiting enzyme in the formation of glucose from lactate, can also decrease hepatic metabolism of lactate. leading to increasing lactic acidosis. Signs and symptoms of Bigovas induced lactic acidosis are nonspecific and include anorexia, nausea, vomiting, altered level of consciousness, hyperpnoea, abdominal pain, and thirst.
Bigovas contain metformin, is an oral antidiabetic drug which belongs to the class of biguanide. It is the first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight. It is also used in the treatment of polycystic ovary syndrome. Moreover, it also reduces the risk of cardiovascular complications of diabetes.
The long-term use can lead to the deficiency of Vitamin B12, which can further lead to megaloblastic anemia. Furthermore, Long-term Metformin use can also lead to kidney and liver problems.
Yes, Bigovas can cause low blood sugar (hypoglycemia). However, this can also occur if you delay or miss a meal, drink alcohol, exercise more than usual, can't eat due to stomach upset, and taking other antidiabetic medicine with metformin. So, regular monitoring of blood glucose level is needed and be cautious of symptoms of hypoglycemia, always keep glucose-rich food with you.
This medicine data has been created by -
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Glucophage® (metformin hydrochloride)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 275-276
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 825-826